Oncology/Hematology
Hematology
More in Hematology
News, features, and commentary about cancer-related issues
Radiation exposure, type and cumulative dose of chemotherapy drive melanoma risk
Incidence of cytokine release syndrome was minimal with the investigational therapy
Also in TTHealthWatch: catheter material for PICC lines
News, features, and commentary about cancer-related issues
Phase III data show promising efficacy with manageable toxicity and feasible delivery
ORR of 80% at recommended dose of talquetamab, teclistamab but with high rates of grade 3/4 AEs
Study suggests that driver mutation monitoring could become standard practice, researcher says
Treatment tied to higher recovery odds and faster time to kidney recovery
FDA boxed warning led to multiple studies on the issue in 2024
News, features, and commentary about cancer-related issues
Studies show promising EFS, PFS, and OS at 3 to 8 years
3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone
Experts weigh the role of MRD in personalizing treatment but caution against premature changes
